JP2023524684A5 - - Google Patents

Info

Publication number
JP2023524684A5
JP2023524684A5 JP2022566065A JP2022566065A JP2023524684A5 JP 2023524684 A5 JP2023524684 A5 JP 2023524684A5 JP 2022566065 A JP2022566065 A JP 2022566065A JP 2022566065 A JP2022566065 A JP 2022566065A JP 2023524684 A5 JP2023524684 A5 JP 2023524684A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
pharmaceutically acceptable
compound
acceptable salt
pi3kα
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022566065A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023524684A (ja
JP7508584B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/029882 external-priority patent/WO2021222556A1/en
Publication of JP2023524684A publication Critical patent/JP2023524684A/ja
Priority to JP2024073451A priority Critical patent/JP2024099776A/ja
Publication of JP2023524684A5 publication Critical patent/JP2023524684A5/ja
Application granted granted Critical
Publication of JP7508584B2 publication Critical patent/JP7508584B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022566065A 2020-04-29 2021-04-29 PI3Kα阻害剤およびそれらの使用 Active JP7508584B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024073451A JP2024099776A (ja) 2020-04-29 2024-04-30 PI3Kα阻害剤およびそれらの使用

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063017571P 2020-04-29 2020-04-29
US63/017,571 2020-04-29
US202063066489P 2020-08-17 2020-08-17
US63/066,489 2020-08-17
PCT/US2021/029882 WO2021222556A1 (en) 2020-04-29 2021-04-29 PI3K-α INHIBITORS AND METHODS OF USE THEREOF

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024073451A Division JP2024099776A (ja) 2020-04-29 2024-04-30 PI3Kα阻害剤およびそれらの使用

Publications (3)

Publication Number Publication Date
JP2023524684A JP2023524684A (ja) 2023-06-13
JP2023524684A5 true JP2023524684A5 (cg-RX-API-DMAC7.html) 2024-05-13
JP7508584B2 JP7508584B2 (ja) 2024-07-01

Family

ID=78373965

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022566065A Active JP7508584B2 (ja) 2020-04-29 2021-04-29 PI3Kα阻害剤およびそれらの使用
JP2024073451A Pending JP2024099776A (ja) 2020-04-29 2024-04-30 PI3Kα阻害剤およびそれらの使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024073451A Pending JP2024099776A (ja) 2020-04-29 2024-04-30 PI3Kα阻害剤およびそれらの使用

Country Status (14)

Country Link
US (3) US12581252B2 (cg-RX-API-DMAC7.html)
EP (1) EP4143196A4 (cg-RX-API-DMAC7.html)
JP (2) JP7508584B2 (cg-RX-API-DMAC7.html)
KR (2) KR20250057919A (cg-RX-API-DMAC7.html)
CN (3) CN122277553A (cg-RX-API-DMAC7.html)
AU (1) AU2021263914B2 (cg-RX-API-DMAC7.html)
BR (1) BR112022021854A2 (cg-RX-API-DMAC7.html)
CA (1) CA3174675A1 (cg-RX-API-DMAC7.html)
CL (2) CL2022002985A1 (cg-RX-API-DMAC7.html)
IL (2) IL325094A (cg-RX-API-DMAC7.html)
MX (1) MX2022013417A (cg-RX-API-DMAC7.html)
PE (1) PE20231073A1 (cg-RX-API-DMAC7.html)
PH (1) PH12022500017A1 (cg-RX-API-DMAC7.html)
WO (1) WO2021222556A1 (cg-RX-API-DMAC7.html)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2021263914B2 (en) * 2020-04-29 2026-07-23 D.E. Shaw Research, Llc PI3K-α inhibitors and methods of use thereof
WO2022213062A1 (en) 2021-03-29 2022-10-06 Nimbus Saturn, Inc. Hpk1 antagonists and uses thereof
TW202334136A (zh) * 2021-11-03 2023-09-01 美商傳達治療有限公司 PI3Kα抑制劑及其製造與使用方法
WO2023098880A1 (zh) * 2021-12-02 2023-06-08 上海翰森生物医药科技有限公司 稠环类衍生物调节剂、其制备方法和应用
WO2023114973A1 (en) 2021-12-17 2023-06-22 Shure Acquisition Holdings, Inc. Adaptive acoustic echo cancellation for a stereo audio signal
TW202333670A (zh) * 2022-01-04 2023-09-01 大陸商海思科醫藥集團股份有限公司 抑制並降解irak4的化合物及其藥物组合物和藥學上的應用
US20250313524A1 (en) * 2022-05-10 2025-10-09 Relay Therapeutics, Inc. Pi3k-alpha inhibitors and methods of use thereof
CN116655602B (zh) * 2022-07-12 2025-09-16 苏州浦合医药科技有限公司 PI3Kα变构抑制剂
IL318203A (en) * 2022-07-12 2025-03-01 Adama Makhteshim Ltd Process for preparing modified benzamides
CN120152713A (zh) * 2022-07-29 2025-06-13 昂胜医疗科技公司 三环芳基衍生物及其组合物和方法
CA3262681A1 (en) * 2022-07-29 2024-02-01 Ensem Therapeutics, Inc. TRICYCLIC ARYL DERIVATIVES, AND ASSOCIATED COMPOSITIONS AND PROCESSES
WO2024030863A1 (en) 2022-08-05 2024-02-08 Scorpion Therapeutics, Inc. Pi3k-alpha inhibitors for the treatment of cancer
US20260041669A1 (en) 2022-08-11 2026-02-12 Relay Therapeutics, Inc. Solid forms of a cdk inhibitor
EP4585596A4 (en) * 2022-09-09 2025-12-10 Shanghai Yingli Pharm Co Ltd Nitrogen-containing heterocyclic compound, pharmaceutical composition thereof and uses thereof
WO2024055992A1 (zh) * 2022-09-14 2024-03-21 南京再明医药有限公司 三环化合物及其应用
JP2025538147A (ja) * 2022-11-02 2025-11-26 ペトラ・ファーマ・コーポレイション 疾患の治療のためのホスホイノシチド3-キナーゼ(pi3k)のアロステリックポケット及びオルソステリックポケットの標的化
JP2025163068A (ja) * 2022-11-02 2025-10-28 ペトラ・ファーマ・コーポレイション 疾患の治療のためのホスホイノシチド3-キナーゼ(pi3k)のアロステリックポケット及びオルソステリックポケットの標的化
WO2024094163A1 (zh) * 2022-11-03 2024-05-10 上海翰森生物医药科技有限公司 多环并环衍生物、其制备方法和应用
CN120676939A (zh) * 2023-01-13 2025-09-19 传达治疗有限公司 Pi3k抑制剂及其制备和使用方法
WO2024153238A1 (zh) * 2023-01-20 2024-07-25 南京再明医药有限公司 四环化合物及其应用
WO2024233256A1 (en) 2023-05-05 2024-11-14 Eli Lilly And Company Imlunestrant or salts thereof for use in treating and preventing central nervous system (cns) metastases in subjects having er+ breast cancer
WO2025165834A1 (en) * 2024-01-31 2025-08-07 Ensem Therapeutics, Inc. Urea derivatives of tricyclic compounds, and compositions and methods thereof
WO2025179441A1 (zh) * 2024-02-27 2025-09-04 上海璎黎药业有限公司 一种三并环结构化合物、其药物组合物及应用

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1743997A (en) 1996-12-20 1998-07-17 Geron Corporation Poly(adp-ribose) polymerase inhibitors to treat diseases associated with cellular senescence
CA2528938A1 (en) 2003-06-13 2005-02-24 Zentaris Gmbh Compounds having inhibitive activity of phosphatidylinositol 3-kinase and methods of use thereof
HRP20130902T1 (hr) 2005-10-07 2013-11-08 Exelixis Inc. PIRIDOPIRIMIDINONSKI INHIBITORI PI3Kalfa
ZA200904857B (en) 2007-02-22 2010-09-29 Merck Serono Sa Quinoxaline compounds and use thereof
WO2009071895A1 (en) 2007-12-04 2009-06-11 Ucb Pharma S.A. Fused thiazole and thiophene derivatives as kinase inhibitors
UA111579C2 (uk) * 2009-08-17 2016-05-25 Інтеллікіне Ллк ГЕТЕРОЦИКЛІЧНІ ПОХІДНІ 2-АМІНОБЕНЗО[d]ОКСАЗОЛУ, ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ НА ЇХ ОСНОВІ ТА ЇХ ЗАСТОСУВАННЯ ДЛЯ ЛІКУВАННЯ ЗАХВОРЮВАННЯ, ПОВ'АНОГО З РІ3-КІНАЗОЮ
WO2011067365A1 (en) 2009-12-03 2011-06-09 Glaxo Group Limited Benzpyrazole derivatives as inhibitors of p13 kinases
RU2573569C2 (ru) * 2009-12-22 2016-01-20 Вертекс Фармасьютикалз Инкорпорейтед Ингибиторы фосфатидилинозитол-3-киназы на основе изоиндолинона
WO2011114148A1 (en) 2010-03-17 2011-09-22 Astrazeneca Ab 4h- [1, 2, 4] triazolo [5, 1 -b] pyrimidin-7 -one derivatives as ccr2b receptor antagonists
JP2013544827A (ja) 2010-11-24 2013-12-19 エクセリクシス, インク. PI3K/mTORの阻害剤としてのベンゾオキサゼピン類ならびにそれらの使用法および製造法
CN102140087B (zh) 2011-01-27 2013-02-13 清华大学 一种色酮类化合物的合成方法
US8846656B2 (en) * 2011-07-22 2014-09-30 Novartis Ag Tetrahydropyrido-pyridine and tetrahydropyrido-pyrimidine compounds and use thereof as C5a receptor modulators
TWI574962B (zh) 2012-11-14 2017-03-21 加拓科學公司 作爲pi3激酶調節劑的芳雜環化合物及其使用方法和用途
TR201904614T4 (en) * 2013-02-27 2019-05-21 Mochida Pharm Co Ltd Novel pyrazole derivative.
JO3368B1 (ar) 2013-06-04 2019-03-13 Janssen Pharmaceutica Nv مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2
JP6472803B2 (ja) 2013-09-05 2019-02-20 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft トリアゾロピリジン化合物、その組成物及び使用方法
WO2017000277A1 (en) 2015-07-01 2017-01-05 Merck Sharp & Dohme Corp. Substituted triazolo bicycliccompounds as pde2 inhibitors
CA2990521C (en) 2015-07-07 2023-10-10 H. Lundbeck A/S Pde9 inhibitors with imidazo triazinone backbone and imidazo pyrazinone backbone for treatment of peripheral diseases
GB201517217D0 (en) 2015-09-29 2015-11-11 Astex Therapeutics Ltd And Cancer Res Technology Ltd Pharmaceutical compounds
EP3400218A4 (en) 2016-01-08 2019-09-18 Euclises Pharmaceuticals, Inc. COMBINATION OF A CHROME CONNECTION AND A SECOND ACTIVE SUBSTANCE
PL3478679T3 (pl) * 2016-07-01 2021-10-25 Pfizer Inc. Pochodne 5,7-dihydro-pirolopirydyny do leczenia chorób neurologicznych i neurodegeneracyjnych
EP3596075B1 (en) * 2017-03-15 2023-10-11 F. Hoffmann-La Roche AG Azaindoles as inhibitors of hpk1
CN109265443B (zh) * 2017-07-18 2022-11-29 南京圣和药业股份有限公司 作为ask抑制剂的杂环化合物及其应用
MY201041A (en) 2017-11-24 2024-01-31 Sumitomo Pharma Co Ltd Substituted pyrazolo[1,5-a]pyrazines as negative allosteric modulators of group ii metabotropic glutamate receptor
RS65576B1 (sr) 2017-11-24 2024-06-28 Jubilant Episcribe Llc Heterociklična jedinjenja kao inhibitori prmt5
US11512054B2 (en) 2017-12-21 2022-11-29 Basf Se Pesticidal compounds
GB201801355D0 (en) 2018-01-26 2018-03-14 Enterprise Therapeutics Ltd Compounds
US12138263B2 (en) 2018-03-21 2024-11-12 Relay Therapeutics, Inc. Pyrazolo[3,4-b]pyrazine SHP2 phosphatase inhibitors and methods of use thereof
EP3931188B1 (en) 2019-02-26 2023-08-30 Boehringer Ingelheim International GmbH New isoindolinone substituted indoles and derivatives as ras inhibitors
GB201905328D0 (en) 2019-04-15 2019-05-29 Azeria Therapeutics Ltd Inhibitor compounds
ES3065954T3 (en) 2019-05-13 2026-05-08 Relay Therapeutics Inc Fgfr inhibitors and methods of use thereof
US12409171B2 (en) 2019-06-20 2025-09-09 University Of Kentucky Research Foundation Pharmaceutically active pyrazolo-pyridone modulators of DCN1/2-mediated cullin neddylation
AU2021263914B2 (en) 2020-04-29 2026-07-23 D.E. Shaw Research, Llc PI3K-α inhibitors and methods of use thereof
US11667636B2 (en) 2020-12-24 2023-06-06 Escient Pharmaceuticals, Inc. Modulators of Mas-related G-protein receptor X2 and related products and methods
AR126447A1 (es) 2021-07-13 2023-10-11 Relay Therapeutics Inc INHIBIDORES DE PI3Ka Y MÉTODOS DE USO DE LOS MISMOS
EP4399196A4 (en) 2021-09-10 2025-08-06 Relay Therapeutics Inc PI3K-ALPHA INHIBITORS AND METHODS OF USE THEREOF
EP4412606A4 (en) 2021-10-07 2025-09-24 Relay Therapeutics Inc PI3K-ALPHA INHIBITORS AND METHODS OF USE THEREOF
TW202334136A (zh) 2021-11-03 2023-09-01 美商傳達治療有限公司 PI3Kα抑制劑及其製造與使用方法
US20260131009A1 (en) 2021-11-03 2026-05-14 Relay Therapeutics, Inc. Bifunctional pi3k-alpha inhibitors and uses thereof
US20250313524A1 (en) 2022-05-10 2025-10-09 Relay Therapeutics, Inc. Pi3k-alpha inhibitors and methods of use thereof
CN120676939A (zh) 2023-01-13 2025-09-19 传达治疗有限公司 Pi3k抑制剂及其制备和使用方法
KR20260113070A (ko) 2023-11-15 2026-07-21 릴레이 테라퓨틱스, 인크. PI3Kα 저해제 그리고 이의 제조 방법 및 사용 방법

Similar Documents

Publication Publication Date Title
JP2024507938A5 (cg-RX-API-DMAC7.html)
JP2022017295A5 (cg-RX-API-DMAC7.html)
JP2022124458A5 (cg-RX-API-DMAC7.html)
JP2022017296A5 (cg-RX-API-DMAC7.html)
JP2024026550A5 (cg-RX-API-DMAC7.html)
JP2006514689A5 (ja) 1−オキソ−2−(2,6−ジオキソピペリジン−3−イル)−4−メチルイソインドリンを含む脳腫瘍の治療及び管理のための医薬組成物
JP2017524735A5 (cg-RX-API-DMAC7.html)
JP2017057230A5 (cg-RX-API-DMAC7.html)
JP2017008088A5 (cg-RX-API-DMAC7.html)
JP2022526850A5 (cg-RX-API-DMAC7.html)
JP2009514880A5 (cg-RX-API-DMAC7.html)
JP2013507415A5 (cg-RX-API-DMAC7.html)
JP2009514881A5 (cg-RX-API-DMAC7.html)
JP2023530351A5 (cg-RX-API-DMAC7.html)
JP2008521928A5 (cg-RX-API-DMAC7.html)
JP2015512398A5 (cg-RX-API-DMAC7.html)
JP2015155440A5 (cg-RX-API-DMAC7.html)
JP2019515908A5 (cg-RX-API-DMAC7.html)
JP2015511609A5 (cg-RX-API-DMAC7.html)
JP2018516936A5 (cg-RX-API-DMAC7.html)
JP2023548055A5 (cg-RX-API-DMAC7.html)
RU2017112088A (ru) Лечение неопластических заболеваний
JP2020536096A5 (cg-RX-API-DMAC7.html)
JP2014512355A5 (cg-RX-API-DMAC7.html)
JP2018528196A5 (cg-RX-API-DMAC7.html)